Rituximab
Treatment for Encephalitis
Typical Dosage: 375 mg/m2 weekly for 4 doses
Effectiveness
75%
Safety Score
40%
Clinical Trials
6
Participants
1K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
375 mg/m2 weekly for 4 doses
Time to Effect
Weeks to 1-2 months
Treatment Duration
Initial course, then maintenance every 6-12 months
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20,000
Monitoring:$5,000
Side Effect Mgmt:$1,000
Total Annual:$26,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$180,000/QALY
QALYs Gained
8
Outcome-Based Costs
Cost per Responder
$37,143
Cost per Remission
$43,333
Rituximab Outcomes
for Encephalitis
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+70%
Remission Rate
+60%
Common Side Effects
Infusion reactions
+40%
Increased infection risk
+8%
PML (Progressive multifocal leukoencephalopathy)
+0.05%
Sources:
Active Clinical Trials
3 active trials recruiting for Rituximab in Encephalitis
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis
NCT03274375RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Paris, France
Started: Jun 23, 2021
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
NCT03194815RECRUITINGPHASE2
70 participants
INTERVENTIONAL
Cambridge, United Kingdom +9 more
Started: Nov 1, 2017
Medium-term Effects of Treatments in Autoimmune Encephalitis
NCT07133113RECRUITING
200 participants
OBSERVATIONAL
Bron, France
Started: Sep 1, 2024
Completed Clinical Trials
3 completed trials for Rituximab in Encephalitis
A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis
NCT00259805COMPLETEDPHASE1
10 participants
INTERVENTIONAL
San Francisco, United States
Started: Jan 1, 2005
B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.
NCT02229942COMPLETEDPHASE3
151 participants
INTERVENTIONAL
Bergen, Norway +4 more
Started: Sep 1, 2014
To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI
NCT03530462COMPLETED
22 participants
OBSERVATIONAL
Hangzhou, China
Started: Apr 7, 2017